First Time Loading...
S

Santhera Pharmaceuticals Holding AG
SIX:SANN

Watchlist Manager
Santhera Pharmaceuticals Holding AG
SIX:SANN
Watchlist
Price: 9.3 CHF -0.75%
Updated: May 3, 2024
Section:
 

Relative Value

The Relative Value of one SANN stock under the Base Case scenario is 171.85 CHF. Compared to the current market price of 9.3 CHF, Santhera Pharmaceuticals Holding AG is Undervalued by 95%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SANN Relative Value
Base Case
171.85 CHF
Undervaluation 95%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

19.1
P/S
P/S
Price to Sales
19.1
vs History
47
vs Industry
34
Median 3Y
19.2
Median 5Y
19.2
Industry
8.1
Forward
11.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-1.6
Median 5Y
-2.8
Industry
26.2
Forward
-1.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-3.2
Industry
22.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-7.7
Median 5Y
-15
Industry
21.3
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
1
Median 3Y
-6.3
Median 5Y
-6.3
Industry
2.5
More Details
24.6
EV/S
EV/S
Enterprise Value to Sales
24.6
vs History
39
vs Industry
25
Median 3Y
23
Median 5Y
23
Industry
7.3
Forward
15
More Details
83.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
83.6
vs History
22
vs Industry
11
Median 3Y
75.7
Median 5Y
37.8
Industry
9.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-4.5
Industry
4.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-3.9
Industry
4.3
Forward
-2.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-3.9
Industry
5.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-3.9
Industry
3.2
More Details
2
EV/IC
EV/IC
Enterprise Value to IC
2
vs History
58
vs Industry
49
Median 3Y
2.1
Median 5Y
2.2
Industry
5
More Details

Multiples Across Competitors

SANN Competitors Multiples
Santhera Pharmaceuticals Holding AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Santhera Pharmaceuticals Holding AG
SIX:SANN
99.5m CHF 19.1 -1.5 -3.4 -2.7
US
Abbvie Inc
NYSE:ABBV
284B USD 5.2 58.9 12.8 19.5
US
Amgen Inc
NASDAQ:AMGN
149.1B USD 5.3 22.2 16.5 24.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.1B USD 10.4 28.5 22.8 23.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
102.6B USD 7.8 25.9 17.4 19.1
AU
CSL Ltd
ASX:CSL
133B AUD 6.2 35.4 21.4 26.6
US
Gilead Sciences Inc
NASDAQ:GILD
81.4B USD 3 168.2 6.7 8.8
US
Moderna Inc
NASDAQ:MRNA
48B USD 7 -10.2 -11 -9.4
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
31.1B USD 3.2 26.6 13.7 17.1
KR
Celltrion Inc
KRX:068270
38.9T KRW 17.9 72.5 44.4 61.1
EV/EBITDA Multiple
EBITDA Growth
CH
S
Santhera Pharmaceuticals Holding AG
SIX:SANN
Average EV/EBITDA: 19.5
Negative Multiple: -3.4 		N/A
US
Abbvie Inc
NYSE:ABBV
12.8
26%
US
Amgen Inc
NASDAQ:AMGN
16.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
59%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
50%
AU
CSL Ltd
ASX:CSL
21.4
54%
US
Gilead Sciences Inc
NASDAQ:GILD
6.7
18%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -11 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -61.9 N/A
US
Biogen Inc
NASDAQ:BIIB
13.7
67%
KR
Celltrion Inc
KRX:068270
44.4
109%

See Also

Summary
SANN intrinsic value, competitors valuation, and company profile.
DCF Valuation
SANN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SANN stock valuation using valuation multiples.
Wall Street Estimates
SANN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SANN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.